Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Brazil prosecutors probe price, intermediary on Bharat vaccine deal

06/22/2021 | 03:14pm EDT

BRASILIA, June 22 (Reuters) - Brazilian federal prosecutors have opened an investigation into a contract worth 1.6 billion reais ($320 million) for 20 million doses of a COVID-19 vaccine made by India's Bharat Biotech, according to a document seen by Reuters on Tuesday.

The prosecutor-general's office (PGR) cited comparatively high prices, speedy talks and pending regulatory approvals as red flags for the Bharat contract signed in February, before similar deals with Pfizer Inc and Johnson & Johnson .

Bharat did not respond to a request for comment outside of business hours in India.

The Bharat contract has also drawn scrutiny from a Brazilian Senate inquiry, which called for testimony on Wednesday from the head of Precisa Medicamentos, Bharat's intermediary in Brasilia.

Justifying the preliminary probe, prosecutors flagged in a document dated June 16 that Precisa's partners include Global Saude, a company accused of selling but not delivering medicine to the Health Ministry in a case under investigation by police.

Precisa said it had no knowledge of the prosecutors' probe and it was open to cooperate with Senate investigators. In a statement, the company said its talks with the Health Ministry were transparent and the price of Bharat's vaccine in Brazil was the same charged in more than a dozen other countries.

The Health Ministry said in a statement on Tuesday that no payment of any kind had been made to Precisa and that its legal department was analysing the case.

Global Saude did not immediately respond to requests for comment.

Prosecutors questioned why the Health Ministry had agreed to buy the Bharat vaccine, which had not cleared regulatory hurdles, for around $15 per dose: significantly more than what it paid for Pfizer's vaccine, which had regulatory approval.

"The history of irregularities involving partners at Precisa and the elevated price paid for the doses under contract ... require deep investigation in both civil and criminal aspects," wrote prosecutors.

In a separate document seen by Reuters, Senate investigators cited testimony from an unnamed public servant describing "abnormal pressures" from senior Health Ministry officials to reach a deal for the Bharat vaccine, branded Covaxin.

In March, Brazilian health regulator Anvisa rejected a request from the government to import doses of Covaxin, citing concerns about Bharat's manufacturing standards as well as a lack of safety data and other documentation.

This month, Anvisa's board agreed to allow the import of just 4 million Covaxin doses for further study of its safety and effectiveness, but the Health Ministry must first sign an agreement with the regulator on key conditions.

($1 = 5.0043 reais) (Reporting by Ricardo Brito Additional reporting by Anthony Boadle Editing by Brad Haynes, Jonathan Oatis and Marguerita Choy)

ę Reuters 2021
Latest news "Economy & Forex"
02:49pMexican economic growth likely picked up steam in second quarter
02:39pGreek tourism faces tense 'summer of patience'
02:34pLawyer who sued Chevron over Ecuador pollution found guilty of contempt
02:34pLawyer who sued Chevron over Ecuador pollution found guilty of contempt
02:28pWORLD BANK : Office of the Chief Economist, Africa Region (AFRCE)
02:15pU.S. will not lift travel restrictions, citing Delta variant -White House
02:15pBezos offers NASA $2 billion in exchange for moon mission contract
02:03pMexican economic growth likely picked up steam in second quarter
02:03pReuters poll - mexico's economy likely grew 1.7% in second quarter vs first quarter
02:03pReuters poll - mexico economy likely grew 19.8% in second quarter 2021 vs same period a year earlier
Latest news "Economy & Forex"